< Back to topics
> Cover Page, Authors, Institutions
> View tables/images/videos
The overall actuarial freedom from bio-chemical progression at 13 years is 81%, while the overall freedom-from-failure for patients having both PSA >10 and Gleason Score 7 was 74%. Of the 41 patients with biochemical failure, 27 (66%) failed within the first three years after treatment. The absolute risk of failure decreased progressively with time, falling to 1% beyond 5 years after treatment. Follow-up biopsies were performed on all failing patients. There were no pathologically documented local failures. The strongest predictor of failure was elevated PAP (p = 0.0001), followed by Gleason Score (p = 0.03) and PSA (p = 0.041). Hormones conferred no survival advantage (p = 0.9) although patients receiving hormones had the most adverse features. Treatment morbidity was limited to temporary RTOG grade 1-2 urinary symptoms. One patient who had both a TUIP and TURP post-treatment developed low-volume stress incontinence. No patient developed rectal ulceration.
Click on images to enlarge (a new pop-up window will open)